Deb Kientop

Deb Kientop, MBA brings over 25 years of experience in oncology drug development, starting in the cancer research labs at the University of Wisconsin, and moving into business development, medical affairs and clinical development roles within pharma and CRO. Her career has included thought leader engagement, product lifecycle planning, strategy development and execution for proposals and bid defenses, and corporate strategy and alliance management. Through her work with oncology investigators and patient advocacy organizations, she has been able to incorporate insights into patient-centric development strategies. Deb is also a published author and cancer patient advocate.

Prior to joining Synteract, Deb was the Vice President of Life Sciences at Inteliquet, a healthcare technology company. Previously, she held senior director strategy positions at two large CROs, as well as numerous biopharmaceutical organizations including MedImmune, MGI Pharma, and Eisai.

Deb holds a Bachelor of Science in Pharmacology and Toxicology, and a Master of Business Administration from the University of Wisconsin.